Validity of multiplex biomarker model of 6 genes for the differential diagnosis of thyroid nodules

被引：7

作者：

Ducena K. ^{[1
]}

Bols A. ^{[1
,2
]}

Vilmanis J. ^{[3
]}

Narbuts Z. ^{[3
]}

Trs J. ^{[4
]}

Andrjeva D. ^{[2
]}

Lin A. ^{[2
]}

Prgs V. ^{[1
,3
]}

机构：

[1] Faculty of Medicine, University of Latvia, Riga, LV1586

[2] Department of Molecular Biology, Latvian Biomedical Research and Study Centre, Riga, LV1067

[3] Surgery Clinics, Pauls Stradins Clinical University Hospital, Riga, LV1002

[4] Oncology Department, Riga Eastern Clinical University Hospital, Riga, LV1038

来源：

Thyroid Research | / 4卷 / 1期

关键词：

Thyroid Cancer; Papillary Thyroid Carcinoma; Thyroid Nodule; Fine Needle Aspiration Biopsy; Malignant Nodule;

D O I：

10.1186/1756-6614-4-11

中图分类号：

学科分类号：

摘要：

Background: Currently the cytological examination of fine needle aspiration (FNA) biopsies is the standard technique for the pre-operative differential diagnosis of thyroid nodules. However, the results may be non-informative in ∼20% of cases due to an inadequate sampling and the lack of highly specific, measurable cytological criteria, therefore ancillary biomarkers that could aid in these cases are clearly needed. The aim of our study was to evaluate the mRNA expression levels of 8 candidate marker genes as the diagnostic biomarkers for the discrimination of benign and malignant thyroid nodules and to find a combination of biomarkers with the highest diagnostic value. Materials and methods. mRNA expression levels of eight candidate marker genes - BIRC5, CCND1, CDH1, CITED1, DPP4, LGALS3, MET and TFF3 was measured by real-time RT-PCR in paired nodular and surrounding normal thyroid tissue specimens of 105 consecutive patients undergoing thyroid surgery and compared between different types of thyroid lesions. Results: Significant differences in the mRNA expression levels between the normal and malignant thyroid tissues and between benign and malignant nodules were found for BIRC5, CCND1, CITED1, DPP4, LGALS3, MET and TFF3, but not CDH1. On a single gene basis, relative quantity (RQ) of LGALS3 had the highest diagnostic value for the discrimination of malignant and benign thyroid nodules (AUC = 0.832, P < 0.0001 and 90.9% sensitivity and 65.6% specificity at the optimal cut-off on ROC curve). The only two-marker set that outperformed LGALS3 was RQ sum of LGALS3 and BIRC5 (AUC = 0.841, P < 0.0001). An application of multivariate logistic regression analysis resulted in the generation of a multiplex biomarker model based on LGALS3, BIRC5, TFF3, CCND1, MET and CITED1 that had considerably higher specificity than a single marker or two marker gene-based models (AUC = 0.895, P < 0.0001, 70.5% sensitivity and 93.4% specificity). Conclusions: This study confirmed that mRNA expression levels of 7 out of 8 candidate genes analysed have a diagnostic value for the distinction of benign and malignant thyroid nodules. The multiplex biomarker model based on 6 genes outperformed a single marker or two marker-based models and warrants feasibility studies on FNA biopsies and the validation in a larger cohort of patients. © 2011 Ducena et al; licensee BioMed Central Ltd.

引用

共 41 条

[1]

Gharib H., Papini E., Valcavi R., Baskin H.J., Crescenzi A., Dottorini M.E., Et al., American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules, Endocr Pract, 12, pp. 63-102, (2006)

[2]

Liu S., Semenciw R., Ugnat A.-M., Mao Y., Increasing thyroid cancer incidence in Canada, 1970-1996: Time trends and age-period-cohort effects, British Journal of Cancer, 85, 9, pp. 1335-1339, (2001)

[3]

Ferlay J., Parkin D.M., Steliarova-Foucher E., Estimates of cancer incidence and mortality in Europe in 2008, Eur J Cancer, 46, pp. 765-781, (2010)

[4]

Kondo T., Ezzat S., Asa S.L., Pathogenetic mechanisms in thyroid follicular-cell neoplasia, Nat Rev Cancer, 6, pp. 292-306, (2006)

[5]

Lloyd R.V., Erickson L.A., Casey M.B., Lam K.Y., Lohse C.M., Asa S.L., Chan J.K.C., DeLellis R.A., Harach H.R., Kakudo K., LiVolsi V.A., Rosai J., Sebo T.J., Sobrinho-Simoes M., Wenig B.M., Lae M.E., Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma, American Journal of Surgical Pathology, 28, 10, pp. 1336-1340, (2004)

[6]

Foukakis T., Gusnanto A., Au A.Y.M., Hoog A., Lui W.-O., Larsson C., Wallin G., Zedenius J., A PCR-based expression signature of malignancy in follicular thyroid tumors, Endocrine-Related Cancer, 14, 2, pp. 381-391, (2007)

[7]

Barden C.B., Shister K.W., Zhu B., Guiter G., Greenblatt D.Y., Zeiger M.A., Fahey III T.J., Classification of follicular thyroid tumors by molecular signature: Results of gene profiling, Clinical Cancer Research, 9, 5, pp. 1792-1800, (2003)

[8]

Finley D.J., Arora N., Zhu B., Gallagher L., Fahey III T.J., Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules, Journal of Clinical Endocrinology and Metabolism, 89, 7, pp. 3214-3223, (2004)

[9]

Finley D.J., Lubitz C.C., Wei C., Zhu B., Fahey III T.J., Advancing the molecular diagnosis of thyroid nodules: Defining benign lesions by molecular profiling, Thyroid, 15, 6, pp. 562-568, (2005)

[10]

Nardone H.C., Ziober A.F., LiVolsi V.A., Mandel S.J., Baloch Z.W., Weber R.S., Mick R., Ziober B.L., c-Met expression in tall cell variant papillary carcinoma of the thyroid, Cancer, 98, 7, pp. 1386-1393, (2003)

← 1 2 3 4 5 →